NCT03581591 is a Phase 3 clinical trial of Burosumab in Hypophosphatemia, sponsored by Redwood Dermatology Sciences.

Who is sponsoring NCT03581591?

NCT03581591 is sponsored by Redwood Dermatology Sciences.

What drugs are being tested in NCT03581591?

Interventions in NCT03581591: Burosumab.

What condition does NCT03581591 study?

NCT03581591 studies Hypophosphatemia, Hypophosphatemic Rickets, Pain, Chronic.

Is NCT03581591 still recruiting?

NCT03581591 is currently completed. Last updated 18 January 2020.

Last reviewed 2020-01-18 · How we verify

NCT03581591

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets

Completed Phase 3 Last updated 18 January 2020

What this trial tests

Phase 3 trial testing Burosumab in Hypophosphatemia in 1 participant. Completed in 6 December 2019.

Timeline

31 January 2018

Primary endpoint
6 December 2019

6 December 2019

Quick facts

Lead sponsor	Redwood Dermatology Sciences
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	1
Start date	31 January 2018
Primary completion	6 December 2019
Estimated completion	6 December 2019
Sites	1 location across United States

Drugs / interventions tested

Burosumab (BUROSUMAB) — full drug profile →

Conditions studied

Hypophosphatemia — all drugs for Hypophosphatemia →
Hypophosphatemic Rickets — all drugs for Hypophosphatemic Rickets →
Pain, Chronic — all drugs for Pain, Chronic →

Sponsor

Redwood Dermatology Sciences

Who can join

Under 18, female only, with Hypophosphatemia or Hypophosphatemic Rickets. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A 52 week, open label trial to assess the safety and efficacy of KRN23, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome(ENS) and associated hypophosphatemic rickets A 26 weeks extension to original study to monitor patient lab results for her safety.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Multi-ancestry genome-wide study identifies effector genes and druggable pathways for coronary artery calcification.
Kavousi M, Bos MM, Barnes HJ, Lino Cardenas CL, et al · · 2023 · cited 88× · PMID 37770635 · DOI 10.1038/s41588-023-01518-4

Verify or expand the search:

Other trials of Burosumab

Trials testing the same drug.

NCT05509595 — Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia · Phase 2 · completed
NCT05181839 — A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth · completed
NCT04695860 — Anti-FGF23 (Burosumab) in Adult Patients With XLH · Phase 3 · completed
NCT04188964 — Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age · Phase 1, PHASE2 · completed
NCT03920072 — Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH · Phase 3 · completed

Other recruiting trials for Hypophosphatemia

Currently open trials in the same condition.

NCT07233889 — Enteral Supplementation With Sodium Dihydrogen Phosphate and Disodium Hydrogen Phosphate Granules for the Treatment of H · NA · recruiting
NCT06754670 — Effect of Hypophosphatemia on Neuro-excursion Efficiency During Mechanical Ventilator Weaning · recruiting
NCT06112236 — Effects of Treatments for Anemia and Iron Deficiency on the Electrolyte Balance in Lung Transplant Recipients: A Special · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03581591 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Redwood Dermatology Sciences
Last refreshed: 18 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03581591.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing